Furthermore, to confirm the repressive function of PRMT5 and HDAC2 on the E-cadherin promoter, we treated SW480-ZEB2 cells with the PRMT5 inhibitor GSK3326595 and the HDAC2 inhibitor Santacruzamate A. As expected, both GSK3326595 and Santacruzamate A treatments rescued the ZEB2-mediated E-cadherin promoter suppression in SW480-ZEB2 cells, confirming that the ZEB2-mediated repression of E-cadherin in CRC cells is facilitated by PRMT5 and HDAC2. This evidence concerns the gene ZEB2 and colorectal carcinoma.